Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Medtronic
Colorcon
Mallinckrodt
Boehringer Ingelheim

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,211,306

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,211,306
Title:Cellular therapeutic agent for incontinence or urine comprising stem cells originated from decidua or adipose
Abstract: The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence.
Inventor(s): Ra; Jeong Chan (Gyeonggi-do, KR), Lee; Hang Young (Gyeonggi-do, KR), Jo; Jung Youn (Seoul, KR), Kim; Yun Jung (Seoul, KR)
Assignee: RNL BIO CO., LTD. (Seoul, KR)
Application Number:13/738,479
Patent Claims:1. A method for treating urinary incontinence in a patient in need thereof, said method comprising: (i) obtaining tissue from the decidua of the placenta or the decidua of menstrual fluid and finely cutting the tissue; (ii) digesting the finely cut tissue in medium containing collagenase, and then removing non-digested tissue; (iii) centrifuging the digested tissues and then suspending the resulting pellets to obtain single cells; (iv) culturing the single cells in a culture vessel in a medium containing bFGF, whereby stem cells attach to the culture vessel; (v) collecting the attached stem cells; (vi) formulating a cellular therapeutic agent comprising the stem cells; and (vii) injecting the cellular therapeutic agent into the patient's lower abdominal region, thereby increasing leak-point pressure, wherein said stem cells have the following characteristics: (a) positive for CD29 and CD90, but negative for CD31 and CD45; (b) positive for Oct4, SSEA-4 and Cripto-1; (c) ability to grow attached to plastic, showing morphological features of round or spindle shape, and forming spheres in serum-free medium so as to be able to be maintained in an undifferentiated state; and (d) having the ability to differentiate into myocytes.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Mallinckrodt
Harvard Business School
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.